Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Target site occupancy: emerging generalizations from clinical and preclinical studies.

Grimwood S, Hartig PR.

Pharmacol Ther. 2009 Jun;122(3):281-301. doi: 10.1016/j.pharmthera.2009.03.002. Epub 2009 Mar 21. Review.

PMID:
19306894
2.

Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.

Lelas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL, Godonis HE, Ren SX, Yan XX, Arneric SP, Robertson DW, Hartig PR, Grossman S, Trainor GL, Taub RA, Zaczek R, Gilligan PJ, McElroy JF.

J Pharmacol Exp Ther. 2004 Apr;309(1):293-302. Epub 2004 Jan 23.

3.

Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Fitzgerald LW, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):129-31.

PMID:
12467632
4.

Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Cain GA, Sun JH, Yan JS, Teleha CA, Fitzgerald LW, McElroy J, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):125-8.

PMID:
12467631
5.

Antisense oligonucleotides for target validation in the CNS.

Ho SP, Hartig PR.

Curr Opin Mol Ther. 1999 Jun;1(3):336-43. Review.

PMID:
11713799
6.

Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor.

Ho SP, Takahashi LK, Livanov V, Spencer K, Lesher T, Maciag C, Smith MA, Rohrbach KW, Hartig PR, Arneric SP.

Brain Res Mol Brain Res. 2001 Apr 18;89(1-2):29-40.

PMID:
11311973
7.

Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors.

Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R.

J Biol Chem. 2000 Nov 3;275(44):34086-91.

8.

Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.

Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW.

Mol Pharmacol. 2000 Jan;57(1):75-81.

9.

Messenger RNA editing of the human serotonin 5-HT2C receptor.

Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran DP, Jonak GJ, Hartig PR.

Neuropsychopharmacology. 1999 Aug;21(2 Suppl):82S-90S.

10.

High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.

Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR.

J Neurochem. 1999 May;72(5):2127-34.

11.

Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects.

Grzanna R, Dubin JR, Dent GW, Ji Z, Zhang W, Ho SP, Hartig PR.

Brain Res Mol Brain Res. 1998 Dec 10;63(1):35-52.

PMID:
9838035
12.

A genome-based receptor nomenclature.

Hartig PR.

Ann N Y Acad Sci. 1997 May 30;812:85-91. Review. No abstract available.

PMID:
9186723
13.

Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes.

Hartig PR, Hoyer D, Humphrey PP, Martin GR.

Trends Pharmacol Sci. 1996 Mar;17(3):103-5. Review.

PMID:
8936345
14.

Modeling and mutagenesis of the human alpha 1a-adrenoceptor: orientation and function of transmembrane helix V sidechains.

Wetzel JM, Salon JA, Tamm JA, Forray C, Craig D, Nakanishi H, Cui W, Vaysse PJ, Chiu G, Weinshank RL, Hartig PR, Branchek TA, Gluchowski C.

Receptors Channels. 1996;4(3):165-77.

PMID:
9014240
15.

The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.

Gerald C, Adham N, Kao HT, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJ, Hartig PR, Branchek TA, et al.

EMBO J. 1995 Jun 15;14(12):2806-15.

16.

Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus.

Kaufman MJ, Hartig PR, Hoffman BJ.

J Neurochem. 1995 Jan;64(1):199-205.

PMID:
7798914
17.

International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP.

Pharmacol Rev. 1994 Jun;46(2):157-203. Review.

PMID:
7938165
18.

The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.

Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.

Mol Pharmacol. 1994 Apr;45(4):703-8.

PMID:
8183249
19.

Molecular pharmacology of serotonin receptors.

Hartig PR.

EXS. 1994;71:93-102. Review.

PMID:
7518266
20.

Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.

Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA.

Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.

21.

Serotonin receptor subtypes.

Hartig PR, Adham N, Zgombick J, Macchi M, Kao HT, Schechter L, Branchek T, Weinshank R.

Psychopharmacol Ser. 1993;10:15-25. Review. No abstract available.

PMID:
8361973
22.

The use of cloned human receptors for drug design.

Hartig PR.

NIDA Res Monogr. 1993;134:58-65. Review. No abstract available.

PMID:
8289886
23.

Transporter explosion: update on uptake.

Uhl GR, Hartig PR.

Trends Pharmacol Sci. 1992 Dec;13(12):421-5. Review. No abstract available.

PMID:
1293865
24.
25.

Cloning and expression of a high affinity taurine transporter from rat brain.

Smith KE, Borden LA, Wang CH, Hartig PR, Branchek TA, Weinshank RL.

Mol Pharmacol. 1992 Oct;42(4):563-9.

PMID:
1435737
26.
27.

Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor.

Zgombick JM, Schechter LE, Macchi M, Hartig PR, Branchek TA, Weinshank RL.

Mol Pharmacol. 1992 Aug;42(2):180-5.

PMID:
1513320
28.

Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors.

Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL.

Neuron. 1992 May;8(5):927-35.

PMID:
1534013
29.

Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.

Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR.

Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.

30.

A subfamily of 5-HT1D receptor genes.

Hartig PR, Branchek TA, Weinshank RL.

Trends Pharmacol Sci. 1992 Apr;13(4):152-9. Review.

PMID:
1589909
31.

Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype.

Zgombick JM, Weinshank RL, Macchi M, Schechter LE, Branchek TA, Hartig PR.

Mol Pharmacol. 1991 Dec;40(6):1036-42.

PMID:
1758439
32.

Molecular cloning and characterization of a high affinity dopamine receptor (D1 beta) and its pseudogene.

Weinshank RL, Adham N, Macchi M, Olsen MA, Branchek TA, Hartig PR.

J Biol Chem. 1991 Nov 25;266(33):22427-35.

33.

Correlation of 125I-LSD autoradiographic labeling with serotonin voltage clamp responses in Aplysia neurons.

Evans ML, Kadan MJ, Hartig PR, Carpenter DO.

Synapse. 1991 May;8(1):22-9.

PMID:
1714633
34.
35.

Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor.

Weinshank RL, Zgombick JM, Macchi M, Adham N, Lichtblau H, Branchek TA, Hartig PR.

Mol Pharmacol. 1990 Nov;38(5):681-8.

PMID:
2172775
36.

The 5-HT1C receptor.

Hartig PR, Hoffman BJ, Kaufman MJ, Hirata F.

Ann N Y Acad Sci. 1990;600:149-66; discussion 166-7. Review. No abstract available.

PMID:
2252307
37.

In vivo labeling of serotonin uptake sites with [3H]paroxetine.

Scheffel U, Hartig PR.

J Neurochem. 1989 May;52(5):1605-12.

PMID:
2523469
38.

Molecular biology of 5-HT receptors.

Hartig PR.

Trends Pharmacol Sci. 1989 Feb;10(2):64-9. Review.

PMID:
2655240
39.

Synthesis and in vivo characterization of D-(+)-(N1-[11C]methyl)-2-Br-LSD: a radioligand for positron emission tomographic studies of serotonin 5-HT2 receptors.

Lever JR, Dannals RF, Wilson AA, Ravert HT, Scheffel U, Hoffman BJ, Hartig PR, Wong DF, Wagner HN Jr.

Int J Rad Appl Instrum B. 1989;16(7):697-704.

PMID:
2575605
40.

Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex.

Blue ME, Yagaloff KA, Mamounas LA, Hartig PR, Molliver ME.

Brain Res. 1988 Jun 21;453(1-2):315-28.

PMID:
3401769
42.

cDNA cloning of a serotonin 5-HT1C receptor by electrophysiological assays of mRNA-injected Xenopus oocytes.

L├╝bbert H, Hoffman BJ, Snutch TP, van Dyke T, Levine AJ, Hartig PR, Lester HA, Davidson N.

Proc Natl Acad Sci U S A. 1987 Jun;84(12):4332-6.

43.

N1-methyl-2-125I-lysergic acid diethylamide, a preferred ligand for in vitro and in vivo characterization of serotonin receptors.

Hoffman BJ, Scheffel U, Lever JR, Karpa MD, Hartig PR.

J Neurochem. 1987 Jan;48(1):115-24.

PMID:
3794694
44.

Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using N1-([11C]-methyl)-2-Br-LSD.

Wong DF, Lever JR, Hartig PR, Dannals RF, Villemagne V, Hoffman BJ, Wilson AA, Ravert HT, Links JM, Scheffel U, et al.

Synapse. 1987;1(5):393-8.

PMID:
2905532
45.

Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice.

Yagaloff KA, Lozano G, van Dyke T, Levine AJ, Hartig PR.

Brain Res. 1986 Oct 22;385(2):389-94.

PMID:
3022874
46.

A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover.

Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR.

Proc Natl Acad Sci U S A. 1986 Jun;83(11):4086-8.

47.

Solubilization and characterization of the serotonin 5-HT1c site from pig choroid plexus.

Yagaloff KA, Hartig PR.

Mol Pharmacol. 1986 Feb;29(2):120-5.

PMID:
3951427
48.
49.

In vivo binding of 125I-LSD to serotonin 5-HT2 receptors in mouse brain.

Hartig PR, Scheffel U, Frost JJ, Wagner HN Jr.

Life Sci. 1985 Aug 19;37(7):657-64.

PMID:
3160905
50.

N1-methyl-2-[125I]LSD ([125I]MIL), a preferred ligand for serotonin 5-HT2 receptors.

Hoffman BJ, Karpa MD, Lever JR, Hartig PR.

Eur J Pharmacol. 1985 Mar 26;110(1):147-8. No abstract available.

PMID:
4007051

Supplemental Content

Loading ...
Support Center